转化酸性卷曲螺旋蛋白3(TACC3)高表达与骨肉瘤不良预后相关
研究纳入33例接受新辅助和辅助化疗及手术切除的经典型骨肉瘤患者,采用免疫组化检测化疗前原发肿瘤标本TACC3表达,分析其与临床病理特征及无事件生存和总生存的关系。高TACC3表达占58%(19/33),与较大肿瘤(AJCC IIB期)、较高p53和Ki-67表达相关,且为无转移生存和总生存的独立不良预后因素。
要点
- 高TACC3表达见于19/33(58%)骨肉瘤标本,与AJCC IIB期、高p53和高Ki-67表达相关。
- 高TACC3表达者5年无转移生存21% vs 低表达者79%,5年总生存34% vs 86%(均p<0.001)。
- 高TACC3表达为无转移生存(HR 3.89)和总生存(HR 4.41)的独立不良预后因素。
核心结论
- 高TACC3表达与这些骨肉瘤患者侵袭性临床病理特征和不良预后相关。
- 作者初步结果提示,进一步分析TACC3的突变或无活性形式有助于理解骨肉瘤患者TACC3异常表达的机制。
- 若这些发现在更大规模研究中得到证实,TACC3可能有助于预测生存并成为骨肉瘤的潜在治疗靶点。
研究设计与样本
- 回顾性分析1989年至2013年在本机构治疗的46例经典型骨肉瘤患者,排除不可切除原发灶2例、未化疗2例、初诊转移5例、无治疗前活检标本2例、无临床病历2例,最终纳入33例。
- 纳入患者接受新辅助和辅助化疗(顺铂/多柔比星/甲氨蝶呤或顺铂/多柔比星/甲氨蝶呤/异环磷酰胺)并完成手术切除且组织学广泛边缘。
- 使用化疗前原发肿瘤标本,通过免疫组化染色检测TACC3表达,统计分析TACC3表达与临床病理特征及无事件生存和总生存的关系。
主要发现
- 33例骨肉瘤标本中19例(58%)观察到高TACC3表达。
- 高TACC3表达与较大肿瘤大小(即本研究中的AJCC IIB期;p=0.002)、较高p53表达(p=0.007)和较高Ki-67表达(p=0.002)相关。
- 高TACC3表达者5年无转移生存估计为21%(95%CI 7%-41%),低TACC3表达者为79%(95%CI 47%-93%)(p<0.001)。
- 高TACC3表达者5年总生存估计为34%(95%CI 13%-56%),低TACC3表达者为86%(95%CI 54%-96%)(p<0.001)。
- 高TACC3表达是无转移生存(HR 3.89,95%CI 1.07-19.78;p=0.039)和总生存(HR 4.41,95%CI 1.01-32.97;p=0.049)的独立不良预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出其结果为初步结果,并建议进一步分析TACC3的突变或无活性形式以理解异常表达机制。
- 作者指出若这些发现在更大规模研究中得到证实,TACC3才可能有助于预测生存并成为潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transforming acidic coiled-coil containing protein 3 (TACC3) is expressed during the mitotic phase of nuclear division and regulates microtubules. Recently, high TACC3 expression in tumor cells of various cancers including soft tissue sarcoma has been reported. However, its role in osteosarcoma remains unknown. Because we have few prognostic markers for survival in osteosarcoma, we wanted to investigate the potential role of TACC3 in human osteosarcoma and determine if it is associated with survival. QUESTIONS/PURPOSES: (1) Is there a relationship between TACC3 expression and clinicopathologic characteristics such as sex, age (< 20 or ≥ 20 years), histologic type (osteoblastic or others), tumor location (femur or others), American Joint Committee on Cancer staging system (AJCC stage IIA or IIB), tumor necrosis percentage after chemotherapy (< 90% or ≥ 90%), p53 expression (low or high), and Ki-67 expression (low or high)? (2) Is TACC3 expression associated with event-free and overall survival in patients with osteosarcoma? METHODS: Forty-six conventional patients with osteosarcoma were treated at our institution from 1989 to 2013. Patients were excluded because of unresectable primary site (two patients) and no chemotherapy (two patients). Patients with metastasis at the initial visit (five patients), without pretreatment biopsy samples (two patients), or clinical charts (two patients) were also excluded. The left 33 patients who received neoadjuvant and adjuvant chemotherapy, which consisted of cisplatin/doxorubicin/methotrexate or cisplatin/doxorubicin/methotrexate/ifosfamide, and completed surgical resection with histologic wide tumor margins. Primary tumor samples before chemotherapy were used in this study. We investigated TACC3 expression using immunohistochemical staining and statistically analyzed the TACC3 expression, clinicopathologic characteristics, and event-free and overall survival in patients with osteosarcoma. RESULTS: High TACC3 expression was observed in 19 of 33 osteosarcoma specimens (58%), and this was associated with larger tumor size (ie, AJCC stage IIB in this study; p = 0.002), higher p53 expression (p = 0.007), and higher Ki-67 expression (p = 0.002). The estimated metastasis-free survival at 5 years was 21% (95% confidence interval [CI], 7%-41%) in patients with high TACC3 expression and 79% (95% CI, 47%-93%) in patients with low TACC3 expression (p < 0.001), and the estimated overall survival at 5 years was 34% (95% CI, 13%-56%) in patients with high TACC3 expression and 86% (95% CI, 54%-96%) in patients with low TACC3 expression (p < 0.001). Furthermore, high TACC3 expression was an independent poor prognostic factor for metastasis-free survival with a hazard ratio of 3.89 (95% CI, 1.07-19.78; p = 0.039) as well as overall survival with 4.41 (95% CI, 1.01-32.97; p = 0.049). CONCLUSIONS: High TACC3 expression was associated with aggressive clinicopathologic features and unfavorable prognosis in these patients with osteosarcoma. Our preliminary results suggest that further analysis about mutation or an inactive form of TACC3 would be useful to understand the mechanism of abnormal TACC3 expression in patients with osteosarcoma. If these findings are substantiated in larger studies, TACC3 might be useful for predicting survival and a potential therapeutic target for osteosarcoma. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Matsuda K, Miyoshi H, Hiraoka K, et al. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma. Clin Orthop Relat Res. 2018. PMID: 30024460. doi:10.1097/CORR.0000000000000379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。